Newborn screening for medium chain acyl-CoA ehydrogenase deficiency in England: Prevalence, redictive value and test validity based on 1.5 million creened babies

Journal of Medical Screening

Volumn 18, Issue 4, 2011, Pages 173-181

  Oerton, Juliet ^a   Khalid, Javaria M ^a   Besley, Guy ^b   Dalton, R Neil ^c   Downing, Melanie ^d   Green, Anne ^e   Henderson, Mick ^f   Krywawych, Steve ^g   Leonard, James ^a   Andresen, Brage S ^h,i   Dezateux, Carol ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b ROYAL MANCHESTER CHILDREN S HOSPITAL   (United Kingdom)

^c EVELINA LONDON CHILDREN S HOSPITAL   (United Kingdom)

^d SHEFFIELD CHILDREN S HOSPITAL   (United Kingdom)

^e BIRMINGHAM CHILDREN S HOSPITAL   (United Kingdom)

^f ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

^g GREAT ORMOND STREET HOSPITAL   (United Kingdom)

^h AARHUS UNIVERSITY HOSPITAL   (Denmark)

ⁱ UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ACYL COENZYME A DEHYDROGENASE;

ARTICLE; ASIAN; CAUCASIAN; CLINICAL TRIAL; DECISION TREE; DISORDERS OF LIPID AND LIPOPROTEIN METABOLISM; ENZYMOLOGY; ETHICS; ETHNIC GROUP; FEMALE; GENETIC SCREENING; GENETIC VARIABILITY; GENETICS; HUMAN; MALE; MEDIUM CHAIN ACYL COENZYME A DEHYDROGENASE DEFICIENCY; METHODOLOGY; MULTICENTER STUDY; NEWBORN; NEWBORN SCREENING; PILOT STUDY; PREDICTIVE VALUE; PREVALENCE; PROSPECTIVE STUDY; REPRODUCIBILITY; STANDARD; UNITED KINGDOM;

ACYL-COA DEHYDROGENASE; ASIAN CONTINENTAL ANCESTRY GROUP; DECISION TREES; ENGLAND; ETHNIC GROUPS; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENETIC TESTING; GENETIC VARIATION; HUMANS; INFANT, NEWBORN; LIPID METABOLISM, INBORN ERRORS; MALE; NEONATAL SCREENING; PILOT PROJECTS; PREDICTIVE VALUE OF TESTS; PREVALENCE; PROSPECTIVE STUDIES; REPRODUCIBILITY OF RESULTS;

EID: 84555196637     PISSN: 09691413     EISSN: 14755793     Source Type: Journal    
DOI: 10.1258/jms.2011.011086     Document Type: Review

References (52)

1. Chace DH, Hillman SL, Van Hove JL, Naylor EW. Rapid diagnosis of MCAD deficiency: quantitative analysis of octanoylcarnitine and other acylcarnitines in newborn blood spots by tandem mass spectrometry. Clin Chem 1997;43:2106-13 (Pubitemid 27497809)
2. Grosse SD, Khoury MJ, Greene CL, Crider KS, Pollitt RJ. The epidemiology of medium chain acyl-CoA dehydrogenase deficiency: an update. Genet Med 2006;8:205-12
3. Maier EM, Liebl B, Roschinger W, et al. Population spectrum of ACADM genotypes correlated to biochemical phenotypes in newborn screening for medium-chain acyl-CoA dehydrogenase deficiency. Hum Mutat 2005;25:443-52 (Pubitemid 40675293)
4. Pourfarzam M, Morris A, Appleton M, Craft A, Bartlett K. Neonatal screening for medium-chain acyl-CoA dehydrogenase deficiency. Lancet 2001;358:1063-4 (Pubitemid 32925130)
5. Zytkovicz TH, Fitzgerald EF, Marsden D, et al. Tandem mass spectrometric analysis for amino, organic, and fatty acid disorders in newborn dried blood spots: a two-year summary from the New England Newborn Screening Program. Clin Chem 2001;47:1945-55 (Pubitemid 33010710)
6. Iafolla AK, Thompson RJ, Jr., Roe CR. Medium-chain acyl-coenzyme A dehydrogenase deficiency: clinical course in 120 affected children. J Pediatr 1994;124:409-15 (Pubitemid 24094451)
7. Pollitt RJ, Leonard JV. Prospective surveillance study of medium chain acyl-CoA dehydrogenase deficiency in the UK. Arch Dis Child 1998;79:116-19 (Pubitemid 28384843)
8. Touma EH, Charpentier C. Medium chain acyl-CoA dehydrogenase deficiency. Arch Dis Child 1992;67:142-5
9. Wilcken B, Hammond J, Silink M. Morbidity and mortality in medium chain acyl coenzyme A dehydrogenase deficiency. Arch Dis Child 1994;70:410-12 (Pubitemid 24183479)
10. Wilson CJ, Champion MP, Collins JE, Clayton PT, Leonard JV. Outcome of medium chain acyl-CoA dehydrogenase deficiency after diagnosis. Arch Dis Child 1999;80:459-62 (Pubitemid 29220184)
11. Leonard JV, Dezateux C. Newborn screening for medium chain acyl CoA dehydrogenase deficiency. Arch Dis Child 2009;94:235-8
12. Lindner M, Hoffmann GF, Matern D. Newborn screening for disorders of fatty-acid oxidation: experience and recommendations from an expert meeting. J Inherit Metab Dis 2010;33:521-6
13. Bodamer OA, Hoffmann GF, Lindner M. Expanded newborn screening in Europe 2007. J Inherit Metab Dis 2007;30:439-44 (Pubitemid 47377039)
14. Rhead WJ. Newborn screening for medium-chain acyl-CoA dehydrogenase deficiency: a global perspective. J Inherit Metab Dis 2006;29:370-7 (Pubitemid 43880637)
15. Waisbren SE, Albers S, Amato S, et al. Effect of expanded newborn screening for biochemical genetic disorders on child outcomes and parental stress. JAMA 2003;290:2564-72 (Pubitemid 37443286)
16. Wilcken B, Haas M, Joy P, et al. Expanded newborn screening: outcome in screened and unscreened patients at age 6 years. Pediatrics 2009;124:e241-8
17. Nennstiel-Ratzel U, Arenz S, Maier EM, et al. Reduced incidence of severe metabolic crisis or death in children with medium chain acyl-CoA dehydrogenase deficiency homozygous for c.985A.G identified by neonatal screening. Mol Genet Metab 2005;85:157-9 (Pubitemid 40724542)
18. Wilcken B, Haas M, Joy P, et al. Outcome of neonatal screening for medium-chain acyl-CoA dehydrogenase deficiency in Australia: a cohort study. Lancet 2007;369:37-42 (Pubitemid 46027226)
19. Gregersen N, Andresen BS, Pedersen CB, Olsen RK, Corydon TJ, Bross P. Mitochondrial fatty acid oxidation defects-remaining challenges. J Inherit Metab Dis 2008;31:643-57
20. Wilcken B. Fatty acid oxidation disorders: outcome and long-term prognosis. J Inherit Metab Dis 2010;31:501-6
21. Andresen BS, Dobrowolski SF, O'Reilly L, et al. Medium-chain acyl-CoA dehydrogenase (MCAD) mutations identified by MS/MS-based prospective screening of newborns differ from those observed in patients with clinical symptoms: identification and characterization of a new, prevalent mutation that results in mild MCAD deficiency. Am J Hum Genet 2001;68:1408-18 (Pubitemid 32510616)
22. Carpenter K, Wiley V, Sim KG, Heath D, Wilcken B. Evaluation of newborn screening for medium chain acyl-CoA dehydrogenase deficiency in 275000 babies. Arch Dis Child 2001;85:F105-9 (Pubitemid 32816614)
23. Zschocke J, Schulze A, Lindner M, et al. Molecular and functional characterisation of mild MCAD deficiency. Hum Genet 2001;108:404-8 (Pubitemid 32492446)
24. Derks TG, Boer TS, van AA, et al. Neonatal screening for medium-chain acyl-CoA dehydrogenase (MCAD) deficiency in The Netherlands: the importance of enzyme analysis to ascertain true MCAD deficiency. J Inherit Metab Dis 2008;31:88-96
25. Maier EM, Pongratz J, Muntau AC, et al. Dissection of biochemical borderline phenotypes in carriers and genetic variants of medium-chain acyl-CoA dehyrogenase deficiency: implications for newborn screening [corrected]. Clin Genet 2009;76:179-87
26. Nichols MJ, Saavedra-Matiz CA, Pass KA, Caggana M. Novel mutations causing medium chain acyl-CoA dehydrogenase deficiency: under-representation of the common c.985 A.G mutation in the New York state population. Am J Med Genet A 2008;146A:610-19
27. Schulze A, Lindner M, Kohlmuller D, Olgemoller K, Mayatepek E, Hoffmann GF. Expanded newborn screening for inborn errors of metabolism by electrospray ionization-tandem mass spectrometry: results, outcome, and implications. Pediatrics 2003;111:1399-406 (Pubitemid 36682277)
28. Derks TG, Duran M,Waterham HR, Reijngoud DJ, Ten Kate LP, Smit GP. The difference between observed and expected prevalence of MCAD deficiency in The Netherlands: a genetic epidemiological study. Eur J Hum Genet 2005;13:947-52 (Pubitemid 41131742)
29. Hoffmann GF, von KR, Klose D, et al. Frequencies of inherited organic acidurias and disorders of mitochondrial fatty acid transport and oxidation in Germany. Eur J Pediatr 2004;163:76-80 (Pubitemid 38223388)
30. Wilcken B. The consequences of extended newborn screening programmes: Do we know who needs treatment? J Inherit Metab Dis 2008;31:173-7
31. Khalid JM, Oerton J, Cortina-Borja M, et al. Ethnicity of children with homozygous c.985A.G medium-chain acyl-CoA dehydrogenase deficiency: findings from screening approximately 1.1 million newborn infants. J Med Screen 2008;15:112-17
32. Moser K, Stanfield KM, Leon DA. Birthweight and gestational age by ethnic group, England and Wales 2005: introducing new data on births. Health Stat Q 2008;39:22-55
33. Pollitt RJ, Green A, McCabe CJ, et al. Neonatal screening for inborn errors of metabolism: cost, yield and outcome. Health Technol Assess 1997;1:i-202
34. Seymour CA, Thomason MJ, Chalmers RA, et al. Newborn screening for inborn errors of metabolism: a systematic review. Health Technol Assess 1997;1:i-95
35. UK Newborn Screening Programme Centre. Standards and Guidelines for Newborn Blood Spot Screening. 31-8-2008. Ref Type: Report
36. Downing M, Manning NJ, Dalton RN, Krywawych S, Oerton J. Detection of urinary hexanoylglycine in the diagnosis of MCAD deficiency from newborn screening. J Inherit Metab Dis 2008;31:550
37. Maegawa GH, Poplawski NK, Andresen BS, et al. Interstitial deletion of 1p22.2p31.1 and medium-chain acyl-CoA dehydrogenase deficiency in a patient with global developmental delay. Am J Med Genet A 2008;146A:1581-6 (Pubitemid 351792406)
38. Morris AA, Taylor RW, Lightowlers RN, Aynsley-Green A, Bartlett K, Turnbull DM. Medium chain acyl-CoA dehydrogenase deficiency caused by a deletion of exons 11 and 12. Hum Mol Genet 1995;4:747-9
39. Andresen BS, Bross P, Udvari S, et al. The molecular basis of medium-chain acyl-CoA dehydrogenase (MCAD) deficiency in compound heterozygous patients: is there correlation between genotype and phenotype? Hum Mol Genet 1997;6:695-707 (Pubitemid 27199063)
40. Arnold GL, Saavedra-Matiz CA, Galvin-Parton PA, et al. Lack of genotype-phenotype correlations and outcome in MCAD deficiency diagnosed by newborn screening in New York State. Mol Genet Metab 2010;99:263-8
41. Hsu HW, Zytkovicz TH, Comeau AM, et al. Spectrum of medium-chain acyl-CoA dehydrogenase deficiency detected by newborn screening. Pediatrics 2008;121:e1108-14
42. Smith EH, Thomas C, McHugh D, et al. Allelic diversity in MCAD deficiency: the biochemical classification of 54 variants identified during 5 years of ACADM sequencing. Mol Genet Metab 2010;100:241-50
43. Waddell L, Wiley V, Carpenter K, et al. Medium-chain acyl-CoA dehydrogenase deficiency: genotype-biochemical phenotype correlations. Mol Genet Metab 2006;87:32-9 (Pubitemid 43003764)
44. Olpin SE, Manning NJ, Pollitt RJ, Bonham JR, Downing M, Clark S. The use of [9,10-3H]myristate, [9,10-3H]palmitate and [9,10-3H]oleate for the detection and diagnosis of medium and long-chain fatty acid oxidation disorders in intact cultured fibroblasts. Adv Exp Med Biol 1999;466:321-5 (Pubitemid 32202275)
45. Goddard P, Hardy D, Hutchin T, Phillips P, Dezateux C, Green A. Quality Assuring a Multicentre Newborn Screening Programme for MCADD in the UK. J Inherit Metab Dis 2005;28 (Suppl. 1):236-P
46. Khalid JM, Oerton J, Besley G, et al. Relationship of octanoylcarnitine concentrations to age at sampling in unaffected newborns screened for medium-chain acyl-CoA dehydrogenase deficiency. Clin Chem 2010;56:1015-21
47. Lynn RM, Pebody R, Knowles R. Twenty years of active paediatric surveillance in the the UK and Republic of Ireland. Euro Surveill 2006;11:E060720
48. Kennedy S, Potter BK,Wilson K, Fisher L, Geraghty M, Milburn J, et al. The first three years of screening for medium chain acyl-CoA dehydrogenase deficiency (MCADD) by newborn screening ontario. BMC Pediatr 2010;10:82
49. Chace DH, DiPerna JC, Mitchell BL, Sgroi B, Hofman LF, Naylor EW. Electrospray tandem mass spectrometry for analysis of acylcarnitines in dried postmortem blood specimens collected at autopsy from infants with unexplained cause of death. Clin Chem 2001;47:1166-82 (Pubitemid 32579103)
50. Downing M, Andresen BS, Bonham J, Dezateux C, Manning NJ, Olpin S. Newborn screening for MCAD deficiency: acylcarnitine C8/C10 ratio at day 6 differentiates affected cases from carriers. J Inherit Metab Dis 2005;28 (Suppl. 1):019-P
51. Lehotay DC, LePage J, Thompson JR, Rockman-Greenberg C. Blood acylcarnitine levels in normal newborns and heterozygotes for medium-chain acyl-CoA dehydrogenase deficiency: a relationship between genotype and biochemical phenotype? J Inherit Metab Dis 2004;27:81-8 (Pubitemid 38418197)
52. Okun JG, Kolker S, Schulze A, et al. A method for quantitative acylcarnitine profiling in human skin fibroblasts using unlabelled palmitic acid: diagnosis of fatty acid oxidation disorders and differentiation between biochemical phenotypes of MCAD deficiency. Biochim Biophys Acta 2002;1584:91-8 (Pubitemid 35217881)